About
With nearly 20 years of experience in biomedical research and corporate management, Timothy C. Mills joined Sanderling as an operating partner in July 1998, and was promoted to Managing Director in 2000. At Sanderling, Dr. Mills has focused on early stage investments in medical devices, biotherapeutics, and i-Health. He serves Sanderling portfolio companies as Director, CEO and Management team member. Prior to joining Sanderling, Dr. Mills served as the Corporate Vice President of New Business Development and Chief Scientific Officer of Target Therapeutics, a medical device company that was acquired by Boston Scientific in 1997. From 1994 to 1997, he was a Director for Prograft Medical, a Target affiliate that was acquired by W.L Gore. Prior to joining Target in 1994, Dr. Mills served as Director of Business Development and Advanced Research & Development in the Interventional Cardiology Division of Baxter Healthcare. Dr. Mills' previous academic appointments included service as
Position in the VCSift Database
- • 7 investors at Sanderling Ventures are tracked.
- • 1,801 investors hold the Managing Director role in VCSift. Timothy C. Mills is one of them.
- • 206 investors are based in San Mateo, California, United States.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Location
- San Mateo, US
Contact Information
Find more investors like Timothy
Search Investors